{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T01:50:49Z","timestamp":1790214649444,"version":"4.1.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,11,15]],"date-time":"2016-11-15T00:00:00Z","timestamp":1479168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,11,15]],"date-time":"2016-11-15T00:00:00Z","timestamp":1479168000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Thioredoxin reductase 1 (TrxR1) is a pivotal intracellular redox sensor and antioxidant enzyme. On the other hand, overexpression of TrxR1 is closely correlated with the initiation of various tumors including breast cancer, though the detailed mechanism remains unclear. Here we investigated the role of TrxR1 in dysplastic transformation of human breast epithelial cell line MCF-10A induced by chronic oxidative stress. Not surprisingly, sustained exposure to H<jats:sub>2<\/jats:sub>O<jats:sub>2<\/jats:sub> significantly augmented the expression and activity of TrxR1 in MCF-10A cells. The dysplastically transformed MCF-10A (MCF-10AT) cells undergoing 8-week H<jats:sub>2<\/jats:sub>O<jats:sub>2<\/jats:sub> treatment exhibited a certain degree of malignancy in tumorigenicity evaluation. Moreover, TrxR1 inhibitor ethaselen (BBSKE) could partially reverse some malignant phenotypes including epithelial to mesenchymal transition (EMT) of MCF-10AT as well as MCF-7 cells. Collectively, our results supported the considerable involvement of TrxR1 in the onset of breast cancer and BBSKE may be a promising agent against breast cancer.<\/jats:p>","DOI":"10.1038\/srep36860","type":"journal-article","created":{"date-parts":[[2016,11,15]],"date-time":"2016-11-15T10:51:10Z","timestamp":1479207070000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Role of thioredoxin reductase 1 in dysplastic transformation of human breast epithelial cells triggered by chronic oxidative stress"],"prefix":"10.1038","volume":"6","author":[{"given":"Chaoran","family":"Dong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruoxuan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanwei","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqing","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huihui","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,11,15]]},"reference":[{"key":"BFsrep36860_CR1","doi-asserted-by":"publisher","first-page":"2627","DOI":"10.1002\/cncr.22656","volume":"109","author":"JG Brody","year":"2007","unstructured":"Brody, J. G. et al. Environmental pollutants, diet, physical activity, body size, and breast cancer: where do we stand in research to identify opportunities for prevention? Cancer 109, 2627\u20132634 (2007).","journal-title":"Cancer"},{"key":"BFsrep36860_CR2","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1056\/NEJMra050776","volume":"354","author":"JD Yager","year":"2006","unstructured":"Yager, J. D. & Davidson, N. E. Estrogen carcinogenesis in breast cancer. N Engl J Med. 354, 270\u2013282 (2006).","journal-title":"N Engl J Med"},{"key":"BFsrep36860_CR3","doi-asserted-by":"crossref","unstructured":"Cavalieri, E., Frenkel, K., Liehr, J. G., Rogan, E. & Roy, D. Estrogens as endogenous genotoxic agents\u2013DNA adducts and mutations. J Natl Cancer Inst Monogr. 75\u201393 (2000).","DOI":"10.1093\/oxfordjournals.jncimonographs.a024247"},{"key":"BFsrep36860_CR4","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S1040-8428(01)00191-3","volume":"44","author":"F Lerebours","year":"2002","unstructured":"Lerebours, F. & Lidereau, R. Molecular alterations in sporadic breast cancer. Crit Rev Oncol Hematol. 44, 121\u2013141 (2002).","journal-title":"Crit Rev Oncol Hematol"},{"key":"BFsrep36860_CR5","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1126\/science.275.5308.1943","volume":"275","author":"J Li","year":"1997","unstructured":"Li, J. et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275, 1943\u20131947 (1997).","journal-title":"Science"},{"key":"BFsrep36860_CR6","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.steroids.2012.11.001","volume":"78","author":"W Yue","year":"2013","unstructured":"Yue, W., Yager, J. D., Wang, J. P., Jupe, E. R. & Santen, R. J. Estrogen receptor-dependent and independent mechanisms of breast cancer carcinogenesis. Steroids 78, 161\u2013170 (2013).","journal-title":"Steroids"},{"key":"BFsrep36860_CR7","doi-asserted-by":"publisher","first-page":"6900","DOI":"10.1021\/bi047629p","volume":"44","author":"Q Felty","year":"2005","unstructured":"Felty, Q. et al. Estrogen-induced mitochondrial reactive oxygen species as signal-transducing messengers. Biochemistry 44, 6900\u20136909 (2005).","journal-title":"Biochemistry"},{"key":"BFsrep36860_CR8","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/B978-0-12-407190-2.00003-4","volume":"119","author":"A Jezierska-Drutel","year":"2013","unstructured":"Jezierska-Drutel, A., Rosenzweig, S. A. & Neumann, C. A. Role of oxidative stress and the microenvironment in breast cancer development and progression. Adv Cancer Res. 119, 107\u2013125 (2013).","journal-title":"Adv Cancer Res"},{"key":"BFsrep36860_CR9","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1039\/C3MT00185G","volume":"6","author":"M Roman","year":"2014","unstructured":"Roman, M., Jitaru, P. & Barbante, C. Selenium biochemistry and its role for human health. Metallomics 6, 25\u201354 (2014).","journal-title":"Metallomics"},{"key":"BFsrep36860_CR10","doi-asserted-by":"publisher","first-page":"8914","DOI":"10.1073\/pnas.1501713112","volume":"112","author":"AI Rozhok","year":"2015","unstructured":"Rozhok, A. I. & DeGregori, J. Toward an evolutionary model of cancer: Considering the mechanisms that govern the fate of somatic mutations. Proc Natl Acad Sci USA 112, 8914\u20138921 (2015).","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFsrep36860_CR11","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.bbagen.2009.01.014","volume":"1790","author":"ES Arner","year":"2009","unstructured":"Arner, E. S. Focus on mammalian thioredoxin reductases\u2013important selenoproteins with versatile functions. Biochim Biophys Acta. 1790, 495\u2013526 (2009).","journal-title":"Biochim Biophys Acta"},{"key":"BFsrep36860_CR12","doi-asserted-by":"publisher","first-page":"24522","DOI":"10.1074\/jbc.274.35.24522","volume":"274","author":"QA Sun","year":"1999","unstructured":"Sun, Q. A. et al. Redox regulation of cell signaling by selenocysteine in mammalian thioredoxin reductases. J Biol Chem. 274, 24522\u201324530 (1999).","journal-title":"J Biol Chem"},{"key":"BFsrep36860_CR13","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1089\/ars.2012.4650","volume":"17","author":"J Lu","year":"2012","unstructured":"Lu, J. & Holmgren, A. Thioredoxin system in cell death progression. Antioxid Redox Signal 17, 1738\u20131747 (2012).","journal-title":"Antioxid Redox Signal"},{"key":"BFsrep36860_CR14","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1089\/ars.2012.4757","volume":"19","author":"DF Mahmood","year":"2013","unstructured":"Mahmood, D. F., Abderrazak, A., El Hadri, K., Simmet, T. & Rouis, M. The thioredoxin system as a therapeutic target in human health and disease. Antioxid Redox Signal 19, 1266\u20131303 (2013).","journal-title":"Antioxid Redox Signal"},{"key":"BFsrep36860_CR15","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1089\/ars.2009.2884","volume":"12","author":"M Selenius","year":"2010","unstructured":"Selenius, M., Rundlof, A. K., Olm, E., Fernandes, A. P. & Bjornstedt, M. Selenium and the selenoprotein thioredoxin reductase in the prevention, treatment and diagnostics of cancer. Antioxid Redox Signal 12, 867\u2013880 (2010).","journal-title":"Antioxid Redox Signal"},{"key":"BFsrep36860_CR16","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1016\/j.bcp.2008.08.021","volume":"76","author":"AG Cox","year":"2008","unstructured":"Cox, A. G., Brown, K. K., Arner, E. S. & Hampton, M. B. The thioredoxin reductase inhibitor auranofin triggers apoptosis through a Bax\/Bak-dependent process that involves peroxiredoxin 3 oxidation. Biochem Pharmacol. 76, 1097\u20131109 (2008).","journal-title":"Biochem Pharmacol"},{"key":"BFsrep36860_CR17","doi-asserted-by":"publisher","first-page":"2784","DOI":"10.1021\/jm001014i","volume":"44","author":"K Becker","year":"2001","unstructured":"Becker, K., Herold-Mende, C., Park, J. J., Lowe, G. & Schirmer, R. H. Human thioredoxin reductase is efficiently inhibited by (2,2\u2032:6\u2032,2\u2032 -terpyridine)platinum(II) complexes. Possible implications for a novel antitumor strategy. J Med Chem. 44, 2784\u20132792 (2001).","journal-title":"J Med Chem"},{"key":"BFsrep36860_CR18","doi-asserted-by":"publisher","first-page":"10021","DOI":"10.1074\/jbc.M115.700591","volume":"291","author":"D Duan","year":"2016","unstructured":"Duan, D., Zhang, J., Yao, J., Liu, Y. & Fang, J. Targeting Thioredoxin Reductase by Parthenolide Contributes to Inducing Apoptosis of HeLa Cells. J Biol Chem. 291, 10021\u201310031 (2016).","journal-title":"J Biol Chem"},{"key":"BFsrep36860_CR19","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.canlet.2016.02.058","volume":"375","author":"P Zou","year":"2016","unstructured":"Zou, P. et al. Piperlongumine as a direct TrxR1 inhibitor with suppressive activity against gastric cancer. Cancer Lett. 375, 114\u2013126 (2016).","journal-title":"Cancer Lett"},{"key":"BFsrep36860_CR20","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1475-2867-10-30","volume":"10","author":"R Yusuf","year":"2010","unstructured":"Yusuf, R. & Frenkel, K. Morphologic transformation of human breast epithelial cells MCF-10A: dependence on an oxidative microenvironment and estrogen\/epidermal growth factor receptors. Cancer Cell Int. 10, 30 (2010).","journal-title":"Cancer Cell Int"},{"key":"BFsrep36860_CR21","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1042\/BJ20091378","volume":"430","author":"AA Turanov","year":"2010","unstructured":"Turanov, A. A. et al. Mammalian thioredoxin reductase 1: roles in redox homoeostasis and characterization of cellular targets. Biochem J. 430, 285\u2013293 (2010).","journal-title":"Biochem J"},{"key":"BFsrep36860_CR22","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.ccell.2014.11.019","volume":"27","author":"IS Harris","year":"2015","unstructured":"Harris, I. S. et al. Glutathione and thioredoxin antioxidant pathways synergize to drive cancer initiation and progression. Cancer Cell. 27, 211\u2013222 (2015).","journal-title":"Cancer Cell"},{"key":"BFsrep36860_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/PAI.0b013e318255bafa","volume":"21","author":"R de Deus Moura","year":"2013","unstructured":"de Deus Moura, R., Wludarski, S. C., Carvalho, F. M. & Bacchi, C. E. Immunohistochemistry applied to the differential diagnosis between ductal and lobular carcinoma of the breast. Appl Immunohistochem Mol Morphol. 21, 1\u201312 (2013).","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"BFsrep36860_CR24","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.anndiagpath.2014.08.007","volume":"18","author":"ES Reisenbichler","year":"2014","unstructured":"Reisenbichler, E. S., Ross, J. R. & Hameed, O. The clinical use of a P63\/cytokeratin7\/18\/cytokeratin5\/14 antibody cocktail in diagnostic breast pathology. Ann Diagn Pathol. 18, 313\u2013318 (2014).","journal-title":"Ann Diagn Pathol"},{"key":"BFsrep36860_CR25","doi-asserted-by":"publisher","first-page":"3816","DOI":"10.1016\/j.bmc.2012.04.033","volume":"20","author":"J He","year":"2012","unstructured":"He, J. et al. Inhibition of thioredoxin reductase by a novel series of bis-1,2-benzisoselenazol-3(2H)-ones: Organoselenium compounds for cancer therapy. Bioorg Med Chem. 20, 3816\u20133827 (2012).","journal-title":"Bioorg Med Chem"},{"key":"BFsrep36860_CR26","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1016\/j.freeradbiomed.2011.11.034","volume":"52","author":"L Wang","year":"2012","unstructured":"Wang, L. et al. Ethaselen: a potent mammalian thioredoxin reductase 1 inhibitor and novel organoselenium anticancer agent. Free Radic Biol Med. 52, 898\u2013908 (2012).","journal-title":"Free Radic Biol Med"},{"key":"BFsrep36860_CR27","doi-asserted-by":"publisher","first-page":"21517","DOI":"10.1074\/jbc.M301032200","volume":"278","author":"S Meiners","year":"2003","unstructured":"Meiners, S. et al. Inhibition of proteasome activity induces concerted expression of proteasome genes and de novo formation of Mammalian proteasomes. J Biol Chem. 278, 21517\u201321525 (2003).","journal-title":"J Biol Chem"},{"key":"BFsrep36860_CR28","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.ccr.2011.11.024","volume":"21","author":"VG Cooke","year":"2012","unstructured":"Cooke, V. G. et al. Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway. Cancer Cell 21, 66\u201381 (2012).","journal-title":"Cancer Cell"},{"key":"BFsrep36860_CR29","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.ccr.2014.07.022","volume":"26","author":"H Zheng","year":"2014","unstructured":"Zheng, H. et al. PKD1 phosphorylation-dependent degradation of SNAIL by SCF-FBXO11 regulates epithelial-mesenchymal transition and metastasis. Cancer Cell 26, 358\u2013373 (2014).","journal-title":"Cancer Cell"},{"key":"BFsrep36860_CR30","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1056\/NEJMoa044383","volume":"353","author":"LC Hartmann","year":"2005","unstructured":"Hartmann, L. C. et al. Benign breast disease and the risk of breast cancer. N Engl J Med. 353, 229\u2013237 (2005).","journal-title":"N Engl J Med"},{"key":"BFsrep36860_CR31","doi-asserted-by":"publisher","first-page":"2671","DOI":"10.1200\/JCO.2006.09.0217","volume":"25","author":"AC Degnim","year":"2007","unstructured":"Degnim, A. C. et al. Stratification of breast cancer risk in women with atypia: a Mayo cohort study. J Clin Oncol. 25, 2671\u20132677 (2007).","journal-title":"J Clin Oncol"},{"key":"BFsrep36860_CR32","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.bbrc.2010.03.083","volume":"396","author":"A Holmgren","year":"2010","unstructured":"Holmgren, A. & Lu, J. Thioredoxin and thioredoxin reductase: current research with special reference to human disease. Biochem Biophys Res Commun. 396, 120\u2013124 (2010).","journal-title":"Biochem Biophys Res Commun"},{"key":"BFsrep36860_CR33","first-page":"2425","volume":"23","author":"DT Lincoln","year":"2003","unstructured":"Lincoln, D. T., Ali Emadi, E. M., Tonissen, K. F. & Clarke, F. M. The thioredoxin-thioredoxin reductase system: over-expression in human cancer. Anticancer Res. 23, 2425\u20132433 (2003).","journal-title":"Anticancer Res"},{"key":"BFsrep36860_CR34","doi-asserted-by":"publisher","first-page":"12288","DOI":"10.1073\/pnas.0701549104","volume":"104","author":"J Lu","year":"2007","unstructured":"Lu, J., Chew, E. H. & Holmgren, A. Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide. Proc Natl Acad Sci USA 104, 12288\u201312293 (2007).","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFsrep36860_CR35","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1093\/carcin\/bgs230","volume":"33","author":"BA Carlson","year":"2012","unstructured":"Carlson, B. A. et al. Thioredoxin reductase 1 protects against chemically induced hepatocarcinogenesis via control of cellular redox homeostasis. Carcinogenesis 33, 1806\u20131813 (2012).","journal-title":"Carcinogenesis"},{"key":"BFsrep36860_CR36","doi-asserted-by":"publisher","first-page":"4684","DOI":"10.1038\/ncomms5684","volume":"5","author":"S Enroth","year":"2014","unstructured":"Enroth, S., Johansson, A., Enroth, S. B. & Gyllensten, U. Strong effects of genetic and lifestyle factors on biomarker variation and use of personalized cutoffs. Nat Commun. 5, 4684 (2014).","journal-title":"Nat Commun"},{"key":"BFsrep36860_CR37","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1089\/15230860260220201","volume":"4","author":"A Mitsui","year":"2002","unstructured":"Mitsui, A. et al. Overexpression of human thioredoxin in transgenic mice controls oxidative stress and life span. Antioxid Redox Signal 4, 693\u2013696 (2002).","journal-title":"Antioxid Redox Signal"},{"key":"BFsrep36860_CR38","doi-asserted-by":"publisher","first-page":"25506","DOI":"10.18632\/oncotarget.4635","volume":"6","author":"Y Jiang","year":"2015","unstructured":"Jiang, Y. et al. Thioredoxin 1 mediates TGF-beta-induced epithelial-mesenchymal transition in salivary adenoid cystic carcinoma. Oncotarget 6, 25506\u201325519 (2015).","journal-title":"Oncotarget"},{"key":"BFsrep36860_CR39","doi-asserted-by":"publisher","first-page":"3625","DOI":"10.7314\/APJCP.2013.14.6.3625","volume":"14","author":"MC Kim","year":"2013","unstructured":"Kim, M. C., Cui, F. J. & Kim, Y. Hydrogen peroxide promotes epithelial to mesenchymal transition and stemness in human malignant mesothelioma cells. Asian Pac J Cancer Prev. 14, 3625\u20133630 (2013).","journal-title":"Asian Pac J Cancer Prev"},{"key":"BFsrep36860_CR40","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1002\/jcp.24922","volume":"230","author":"PK Mahalingaiah","year":"2015","unstructured":"Mahalingaiah, P. K., Ponnusamy, L. & Singh, K. P. Chronic oxidative stress leads to malignant transformation along with acquisition of stem cell characteristics, and epithelial to mesenchymal transition in human renal epithelial cells. J Cell Physiol. 230, 1916\u20131928 (2015).","journal-title":"J Cell Physiol"},{"key":"BFsrep36860_CR41","doi-asserted-by":"publisher","first-page":"e87371","DOI":"10.1371\/journal.pone.0087371","volume":"9","author":"PK Mahalingaiah","year":"2014","unstructured":"Mahalingaiah, P. K. & Singh, K. P. Chronic oxidative stress increases growth and tumorigenic potential of MCF-7 breast cancer cells. PLoS One 9, e87371 (2014).","journal-title":"PLoS One"},{"key":"BFsrep36860_CR42","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.canlet.2005.05.010","volume":"236","author":"F Zhao","year":"2006","unstructured":"Zhao, F. et al. A thioredoxin reductase inhibitor induces growth inhibition and apoptosis in five cultured human carcinoma cell lines. Cancer Lett. 236, 46\u201353 (2006).","journal-title":"Cancer Lett"},{"key":"BFsrep36860_CR43","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s10637-009-9235-7","volume":"28","author":"Q Tan","year":"2010","unstructured":"Tan, Q. et al. Augmented antitumor effects of combination therapy of cisplatin with ethaselen as a novel thioredoxin reductase inhibitor on human A549 cell in vivo. Invest New Drugs 28, 205\u2013215 (2010).","journal-title":"Invest New Drugs"},{"key":"BFsrep36860_CR44","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/s10637-010-9401-y","volume":"29","author":"JN Fu","year":"2011","unstructured":"Fu, J. N. et al. Thioredoxin reductase inhibitor ethaselen increases the drug sensitivity of the colon cancer cell line LoVo towards cisplatin via regulation of G1 phase and reversal of G2\/M phase arrest. Invest New Drugs 29, 627\u2013636 (2011).","journal-title":"Invest New Drugs"},{"key":"BFsrep36860_CR45","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1016\/j.febslet.2015.05.002","volume":"589","author":"R Bill","year":"2015","unstructured":"Bill, R. & Christofori, G. The relevance of EMT in breast cancer metastasis: Correlation or causality? FEBS Lett. 589, 1577\u20131587 (2015).","journal-title":"FEBS Lett"},{"key":"BFsrep36860_CR46","first-page":"711","volume":"23","author":"Y Fu","year":"2014","unstructured":"Fu, Y. et al. Evaluation of thioredoxin reductase as a novel biomarker in the diagnosis and treatment of breast cancer. Journal of Chinese Pharmaceutical Sciences 23, 711\u2013715 (2014).","journal-title":"Journal of Chinese Pharmaceutical Sciences"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep36860.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep36860","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep36860.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T00:14:59Z","timestamp":1672877699000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep36860"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,15]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,12,23]]}},"alternative-id":["BFsrep36860"],"URL":"https:\/\/doi.org\/10.1038\/srep36860","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,15]]},"assertion":[{"value":"1 June 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"36860"}}